Regulation of myelopoiesis through syntenin-mediated modulation of IL-5 receptor output

Blood

Volumn 114, Issue 18, 2009, Pages 3917-3927

  Beekman, Jeffrey M ^a   Verhagen, Liesbeth P ^a   Geijsen, Niels ^b   Coffer, Paul J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; INTERLEUKIN 5; INTERLEUKIN 5 RECEPTOR; INTERLEUKIN 5 RECEPTOR ALPHA; SYNTENIN; CD34 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IL5RA PROTEIN, HUMAN;

ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; ENDOSOME; EOSINOPHIL; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MYELOPOIESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; CELL MEMBRANE; CELL STRAIN HL 60; CYTOLOGY; METABOLISM; PHYSIOLOGY; PROTEIN STABILITY; SIGNAL TRANSDUCTION; UPREGULATION;

ANTIGENS, CD34; CELL DIFFERENTIATION; CELL MEMBRANE; EOSINOPHILS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELLS; HL-60 CELLS; HUMANS; INTERLEUKIN-5 RECEPTOR ALPHA SUBUNIT; MYELOPOIESIS; PROTEIN STABILITY; RECEPTORS, GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; SIGNAL TRANSDUCTION; SYNTENINS; UP-REGULATION;

EID: 70449730684     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-03-208850     Document Type: Article

References (54)

1. Robb L. Cytokine receptors and hematopoietic differentiation. Oncogene. 2007;26(47):6715-6723.
2. Miyajima A, Kitamura T, Harada N, Yokota T, Arai K. Cytokine receptors and signal transduction. Annu Rev Immunol. 1992;10:295-331.
3. Pawson T. Dynamic control of signaling by modular adaptor proteins. Curr Opin Cell Biol. 2007;19(2):112-116.
4. Martinez-Moczygemba M, Huston DP. Biology of common beta receptor-signaling cytokines: IL-3, IL-5, and GM-CSF. J Allergy Clin Immunol. 2003;112(4):653-665.
5. de Groot RP, Coffer PJ, Koenderman L. Regulation of proliferation, differentiation and survival by the IL-3/IL-5/GM-CSF receptor family. Cell Signal. 1998;10(9):619-628.
6. Geijsen N, Koenderman L, Coffer PJ. Specificity in cytokine signal transduction: lessons learned from the IL-3/IL-5/GM-CSF receptor family. Cytokine Growth Factor Rev. 2001;12(1):19-25.
7. Kondo M, Scherer DC, Miyamoto T, et al. Cell-fate conversion of lymphoid-committed progenitors by instructive actions of cytokines. Nature. 2000;407(6802):383-386.
8. Iwasaki-Arai J, Iwasaki H, Miyamoto T, Watanabe S, Akashi K. Enforced granulocyte/macrophage colony-stimulating factor signals do not support lymphopoiesis, but instruct lymphoid to myelomonocytic lineage conversion. J Exp Med. 2003;197(10):1311-1322.
9. Bruno L, Hoffmann R, McBlane F, et al. Molecular signatures of self-renewal, differentiation, and lineage choice in multipotential hemopoietic progenitor cells in vitro. Mol Cell Biol. 2004;24(2):741-756.
10. Evans CA, Pierce A, Winter SA, et al. Activation of granulocyte- macrophage colony-stimulating factor and interleukin-3 receptor subunits in a multipotential hematopoietic progenitor cell line leads to differential effects on development. Blood. 1999;94(5):1504-1514.
11. Kopf M, Brombacher F, Hodgkin PD, et al. IL-5-deficient mice have a developmental defect in CD5+ B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses. Immunity. 1996;4(1):15-24.
12. Yoshida T, Ikuta K, Sugaya H, et al. Defective B-1 cell development and impaired immunity against Angiostrongylus cantonensis in IL-5R alpha-deficient mice. Immunity. 1996;4(5):483-494.
13. Simon D, Braathen LR, Simon HU. Anti-interleukin-5 antibody therapy in eosinophilic diseases. Pathobiology. 2005;72(6):287-292.
14. Sanderson CJ, Warren DJ, Strath M. Identification of a lymphokine that stimulates eosinophil differentiation in vitro. Its relationship to interleukin 3, and functional properties of eosinophils produced in cultures. J Exp Med. 1985;162(1):60-74.
15. Buitenhuis M, Baltus B, Lammers JW, Coffer PJ, Koenderman L. Signal transducer and activator of transcription 5a (STAT5a) is required for eosinophil differentiation of human cord blood-derived CD34+ cells. Blood. 2003;101(1):134-142.
16. Moon BG, Takaki S, Miyake K, Takatsu K. The role of IL-5 for mature B-1 cells in homeostatic proliferation, cell survival, and Ig production. J Immunol. 2004;172(10):6020-6029.
17. Geijsen N, Uings IJ, Pals C, et al. Cytokine-specific transcriptional regulation through an IL-5Ralpha interacting protein. Science. 2001;293(5532):1136-1138.
18. Beekman JM, Coffer PJ. The ins and outs of syntenin, a multifunctional intracellular adaptor protein. J Cell Sci. 2008;121(pt 9):1349-1355.
19. Estrach S, Legg J, Watt FM. Syntenin mediates Delta1-induced cohesiveness of epidermal stem cells in culture. J Cell Sci. 2007;120(pt 16):2944-2952.
20. Beekman JM, Bakema JE, van der LJ, et al. Modulation of FcgammaRI (CD64) ligand binding by blocking peptides of periplakin. J Biol Chem. 2004;279(32):33875-33881.
21. Rosas M, Uings IJ, van Aalst C, et al. Functional analysis of the interleukin-5 receptor antagonist peptide AF18748. Cytokine. 2004;26(6):247-254.
22. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem. 1951;193(1):265-275.
23. Baltus B, Buitenhuis M, van Dijk TB, et al. C/EBP regulates the promoter of the eosinophil-derived neurotoxin/RNS2 gene in human eosinophilic cells. J Leukoc Biol. 1999;66(4):683-688.
24. Pals CM, Verploegen SA, Raaijmakers JA, et al. Identification of cytokine-regulated genes in human leukocytes in vivo. J Allergy Clin Immunol. 2000;105(4):760-768.
25. Martinez-Moczygemba M, Huston DP. Proteasomal regulation of betac signaling reveals a novel mechanism for cytokine receptor heterotypic desensitization. J Clin Invest. 2001;108(12):1797-1806.
26. Martinez-Moczygemba M, Huston DP, Lei JT. JAK kinases control IL-5 receptor ubiquitination, degradation, and internalization. J Leukoc Biol. 2007;81(4):1137-1148.
27. Ogata N, Kouro T, Yamada A, et al. JAK2 and JAK1 constitutively associate with an interleukin-5 (IL-5) receptor alpha and betac subunit, respectively, and are activated upon IL-5 stimulation. Blood. 1998;91(7):2264-2271.
28. Stafford S, Lowell C, Sur S, Alam R. Lyn tyrosine kinase is important for IL-5-stimulated eosinophil differentiation. J Immunol. 2002;168(4):1978-1983.
29. van Dijk TB, Caldenhoven E, Raaijmakers JA, et al. The role of transcription factor PU. 1 in the activity of the intronic enhancer of the eosinophilderived neurotoxin (RNS2) gene. Blood. 1998;91(6):2126-2132.
30. Milburn MV, Hassell AM, Lambert MH, et al.Anovel dimer configuration revealed by the crystal structure at 2.4Aresolution of human interleukin-5. Nature. 1993;363(6425):172-176.
31. Hansen G, Hercus TR, McClure BJ, et al. The structure of the GM-CSF receptor complex reveals a distinct mode of cytokine receptor activation. Cell. 2008;134(3):496-507.
32. Kang BS, Cooper DR, Jelen F, et al. PDZ tandem of human syntenin: crystal structure and functional properties. Structure. 2003;11(4):459-468.
33. Nagai T, Ibata K, Park ES, et al. A variant of yellow fluorescent protein with fast and efficient maturation for cell-biological applications. Nat Biotechnol. 2002;20(1):87-90.
34. Remy I, Michnick SW. Application of protein-fragment complementation assays in cell biology. Biotechniques. 2007;42(2):137, 139, 141.
35. Latysheva N, Muratov G, Rajesh S, et al. Syntenin-1 is a new component of tetraspanin-enriched microdomains: mechanisms and consequences of the interaction of syntenin-1 with CD63. Mol Cell Biol. 2006;26(20):7707-7718.
36. Tomoda T, Kim JH, Zhan C, Hatten ME. Role of Unc51.1 and its binding partners in CNS axon outgrowth. Genes Dev. 2004;18(5):541-558.
37. Zimmermann P, Zhang Z, Degeest G, et al. Syndecan recycling [corrected] is controlled by syntenin-PIP2 interaction and Arf6. Dev Cell. 2005;9(3):377-388.
38. Laiosa CV, Stadtfeld M, Graf T. Determinants of lymphoid-myeloid lineage diversification. Annu Rev Immunol. 2006;24:705-738.
39. Hogan SP, Rothenberg ME. Eosinophil function in eosinophil-associated gastrointestinal disorders. Curr Allergy Asthma Rep. 2006;6(1):65-71.
40. Afkarian M, Sedy JR, Yang J, et al. T-bet is a STAT1-induced regulator of IL-12R expression in naive CD4+ T cells. Nat Immunol. 2002;3(6):549-557.
41. Becskei A, Grusby MJ. Contribution of IL-12R mediated feedback loop to Th1 cell differentiation. FEBS Lett. 2007;581(27):5199-5206.
42. Kaiko GE, Horvat JC, Beagley KW, Hansbro PM. Immunological decision-making: how does the immune system decide to mount a helper T-cell response? Immunology. 2008;123(3):326-338.
43. Zhou M, Ouyang W. The function role of GATA-3 in Th1 and Th2 differentiation. Immunol Res. 2003;28(1):25-37.
44. Dorman SC, Sehmi R, Gauvreau GM, et al. Kinetics of bone marrow eosinophilopoiesis and associated cytokines after allergen inhalation. Am J Respir Crit Care Med. 2004;169(5):565-572.
45. Tavernier J, Van der HJ, Verhee A, et al. Interleukin 5 regulates the isoform expression of its own receptor alpha-subunit. Blood. 2000;95(5):1600-1607.
46. Robinson DS, North J, Zeibecoglou K, et al. Eosinophil development and bone marrow and tissue eosinophils in atopic asthma. Int Arch Allergy Immunol. 1999;118(2-4):98-100.
47. McClure BJ, Hercus TR, Cambareri BA, et al. Molecular assembly of the ternary granulocyte-macrophage colony-stimulating factor receptor complex. Blood. 2003;101(4):1308-1315.
48. Cierpicki T, Bushweller JH, Derewenda ZS. Probing the supramodular architecture of a multidomain protein: the structure of syntenin in solution. Structure. 2005;13(2):319-327.
49. Grembecka J, Cierpicki T, Devedjiev Y, et al. The binding of the PDZ tandem of syntenin to target proteins. Biochemistry. 2006;45(11):3674-3683.
50. Zimmermann P, Meerschaert K, Reekmans G, et al. PIP(2)-PDZ domain binding controls the association of syntenin with the plasma membrane. Mol Cell. 2002;9(6):1215-1225.
51. Hardy RR. B-1 B cell development. J Immunol. 2006;177(5):2749-2754.
52. Schilham MW, Oosterwegel MA, Moerer P, et al. Defects in cardiac outflow tract formation and pro-B-lymphocyte expansion in mice lacking Sox-4. Nature. 1996;380(6576):711-714.
53. Simon D, Simon HU. Eosinophilic disorders. J Allergy Clin Immunol. 2007;119(6):1291-1300.
54. Rothenberg ME, Klion AD, Roufosse FE, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008;358(12):1215-1228.